82 results about "Corneal transplantation" patented technology

The invention aims at providing a novel full-thickness biological cornea used for transplantation. The full-thickness biological cornea takes an animal cornea acellular matrix as a carrier, and the acellular matrix comprises animal cornea matrix cells, epithelial cells and endothelial cells which are cultured and augmented in vitro. The cornea is characterized in that the xenogenic corneal acellular matrix prepared by a biochemical method can be used as a good carrier for in vitro constructing the biological cornea in the aspects of shape, structure and biological compatibility, the matrix cells, epithelial cells and endothelial cells of the cornea are planted respectively, and dynamically cultured in the simulated in vivo environment of a biological reactor, so that the full-thickness biological cornea with nearly normal tissue structure and characteristics can be constructed in vitro, and the biological cornea can be used to simulate the physiological cornea for fundamental research on physiology, pathology and pharmacology; moreover, the biological cornea can also be directly used as the donator for corneal transplantation.

A system for performing a corneal transplantation includes a laser source for generating a laser beam and a chair for positioning a patient relative to the laser source. A stabilizing element, engageable with the laser source, is fixated on the anterior surface of the patient's cornea to hold the cornea in alignment with the laser source. The laser source is then used to remove diseased tissue from the cornea of the patient, thereby creating a corneal cavity of known dimensions. In a subsequent step, a donor graft that was previously photoaltered to have substantially the same dimensions as the corneal cavity, is transplanted into the corneal cavity.

This invention discloses methods to attach and grow a monolayer of cultured human corneal endothelial cells onto the endothelial side of the stroma synthesized from biopolymer to generate a more bio-equivalent artificial cornea. The approaches will include the use of attachment and growth promoting agents such as fibronectin, laminin, RGDS, collagen type IV, bFGF conjugated with polycarbophil, and EGF conjugated with polycarbophil. The patent also describes a method to create a self-sustaining polymer containing adhesive molecules and growth factors to support the attachment and proliferation of cultured human corneal endothelial cells for corneal transplantation either as a half-thickness device or full-thickness button replacement. An approach for the implantation of cultured retinal pigment epithelial (RPE) cells into the sub-retinal space for treatment of age-related macular degeneration (ARMD) is disclosed in this invention. This method will enable the delivery of the transplanted RPE in a sheet of monolayer cells and will be better suited to perform their physiological function.

A planning device generating control data for a treatment apparatus for cornea transplantation using a laser device to separate a corneal volume by at least one cut surface in the cornea and to separate a transplant, from a surrounding transplantation material by at least one cut surface wherein the planning device includes an interface supplying measurement data relating to parameters of the cornea. A computer defines a corneal cut surface which confines the corneal volume to be removed, and determines a transplant cut surface by using the transplantation material data and depending on the defined corneal cut surface. The transplant cut surface confines the transplant, and the computer generates one control data for each cut surface to control the laser, wherein the respective cut surfaces can be produced by the laser to isolate the corneal volume and the transplant and to make them removable.

The invention relates to a reconstruction method of tissue engineering human corneal epithelium. The method comprises the following steps of: adopting a DMEM/F12 culture medium containing 20% calf serum to carry out the in vitro culture on human corneal epithelium cells to a logarithmic growth phase, and adopting trypsin and a trypsin-EDTA digestion method to obtain a digestive amniotic carrier bracket of which the epithelium is completely removed; and after the digestive amniotic carrier bracket of which the epithelium is removed is flatly laid in a plug-in Petri dish and is firmly and pasted in a drying way, inoculating the human corneal epithelium cells at the logarithmic growth phase suspended in the DMEM/F12 culture medium containing IV type collagen and 20% calf serum to the plug-inPetri dish flatly laid with the digestive amniotic carrier bracket of which the epithelium is removed, and carrying out the in vitro reconstruction on the tissue engineering human corneal epithelium by a gas-liquid interface culture method. The invention has scientific and reasonable process, the reconstructed tissue engineering human corneal epithelium can be used for mass production, a lot of demands of vast blind patients with corneal epithelium diseases for the tissue engineering human corneal epithelium in clinical corneal transplantation treatment can be met, and the costs of the in vitro reconstruction and clinical treatment of the tissue engineering human corneal epithelium are low.

The invention provides a tacrolimus ophthalmic preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. According to the present invention, thetacrolimus ophthalmic preparation has a micro-emulsion-like structure, is clarified and transparent, has good patient compliance, is prepared from tacrolimus, oil for injection, a surfactant, a stabilizer, an osmotic pressure regulator, a preservative, a pH value regulator, a tackifier and water for injection, and is used for preventing and treating immunological rejection after corneal transplantation or immunological corneal xerosis and conjunctival xerosis. According to the present invention, with the tacrolimus ophthalmic preparation, the problem of the water insolubilization of tacrolimusis solved, the tacrolimus is firstly prepared into the clarified and transparent eye drops with the micro-emulsion-like structure, the irritation on the eyes by the existing tacrolimus-suspended ophthalmic eye drops can be substantially reduced, and the patient compliance can be improved, such that the tacrolimus ophthalmic preparation of the present invention is suitable for the long-term use byimmunological rejection after corneal transplantation, corneal xerosis and conjunctival xerosis, and other patients with indications.

The invention relates to a preparation method of an immunosuppressive activity plantago seed extractive and applications thereof. The preparation method comprises the following steps of: degreasing raw materials and obtaining crude extractive through water extraction and alcohol precipitation; deproteinizing and depigmenting the crude extractie through dialysis and ion exchange chromatography; and removing micromolecular chemical compositions to prepare the plantago seed extractive with higher purity. A total polysaccharide content in the inventive immunosuppressive activity plantago seed extractive accounts more than 72% of the extractive by weight. Shown by a great amount of pharmacological experiments, the plantago seed extractive has immunosuppressive activity, can be used for preparing immune inhibitors in various preparation forms or used as a raw material medicine for preparing other immunosuppressive medicines and used for medical purposes in treating diseases related to immune inflammatory injuries, such as nephritis, cystitis, prostatitis, urethritis, edema and eye diseases, such as uveitis, interstitial keratitis, corneal transplantation rejection, and the like.

The invention relates to a corneal posterior lamella. The corneal posterior lamella is prepared by the following method: (a) separating and culturing cat corneal endothelial precursor cells for obtaining corneal endothelial precursor cells; (b) preparing a porcine corneal acellular matrix and obtaining the acellular matrix; and (c) constructing the corneal posterior lamella. The invention further provides a use of using the corneal posterior lamella as a donor for corneal transplantation. The structure of the tissue engineering corneal posterior lamella constructed by the corneal endothelial precursor cells is similar to the structure of the normal corneal posterior lamella. The construction of the corneal posterior lamella by taking the corneal endothelial precursor cells as seeds can provide sufficient cell sources, overcome the difficult problem of low proliferation capacity of the corneal endothelial cells and simultaneously solve the problems of cell transformation and safety.

The present invention relates to a sheet for corneal transplants comprising corneal endothelial cells on a gelatin hydrogel, which is obtainable by seeding and culturing corneal endothelial cells on a gelatin hydrogel coated with collagen. The sheet of the present invention is extremely useful as a sheet for corneal transplants not only for its biocompatibility and biodegradability, but also for its high transparency.

The invention relates to a method for preparing a carrier bracket of tissue engineering artificial corneal endothelium by using a fresh amniotic membrane. The method comprises the following steps: soaking and disinfecting the fresh amniotic membrane by tobramycin sulfate injection according to the mass ratio of 1:1000; after reverse digestion using trypsin-EDTA digestive juice, lightly scraping the epithelial surface of the amniotic membrane by a cell scraper to completely remove residual epithelial cells to obtain the denuded amniotic membrane which is tiled in culture plate holes for fixingand dry-posting; coating by special coating liquid for the denuded amniotic membrane; and sucking and then drying the coating liquid to obtain the carrier bracket of the tissue engineering artificialcorneal endothelium. The method has scientific and reasonable process, the prepared carrier bracket can be mass produced to meet the heavy demand of scale reconstruction of the tissue engineering artificial corneal endothelium and create conditions for sight rehabilitation of corneal endothelium blindness through clinical corneal transplantation, and the preparation method of the carrier bracket has low cost in in-vitro reconstruction and clinical treatment of the tissue engineering artificial corneal endothelium.

The invention discloses a scaffold material for clinical cornea reconstruction and a preparation method of the material, belongs to the field of medical biomaterials, and mainly aims at solving the present problems that the clinical supply of cornea donors is difficult and the success rate of operations is low. The cornea is reconstructed by providing a keratocyte growth matrix for a cornea receptor. The material prepared by the method is prepared by adjusting pH values of polyose and a collagen solution to be within a certain range at a certain environmental temperature and then conducting crosslinking membrane forming. The material is stable, uniform, transparent, water-proof and pressure-resistant, and is good in biocompatibility. The cornea reconstruction of the corneal transplantation receptor is facilitated.

The invention provides a corneal trephine. The corneal trephine comprises a body part in a hollow cylindrical shape, a knife part in an approximate hollow cylindrical shape, and a finger holding part, wherein the thickness of a column wall of the knife part is gradually reduced from top to bottom; a knife edge for annular cutting is formed at the bottommost end of the column wall; an upper end of the knife edge is fixedly connected with a lower end of the body part; a central shaft line of the knife edge is overlapped with that of the body part; finger holding part comprises a hollow cylindrical body and lug bodies symmetrically fixed to an outer side surface of the hollow cylindrical body, the hollow cylindrical body of the finger holding part can be rotationally sleeved onto the body part; and an alignment device is also arranged on the finger holding part. When being used for corneal transplantation, the corneal trephine can be easily and accurately fixed to a cornea of a patient so as to avoid shifting or separation of the corneal trephine in the corneal transplantation, a proper and uniform pressure can be easily applied to the corneal trephine, and a knife feeding situation can be conveniently observed, thereby enabling the corneal transplantation to be safer and accurate.

The invention belongs to the field of keratoprosthesis stent materials and provides a fiber-enhanced drug-loading hydrogel keratoprosthesis skirt stent and a preparation method thereof. The skirt stent comprises the following components in percentage by weight: 6wt%-10wt% of fibers, 8wt%-15wt% of biodegradable drug-loading microspheres and 75wt%-86wt% of hydrophilic hydrogel, wherein the fibers are disorderedly distributed in hydrophilic hydrogel. The fiber-enhanced drug-loading hydrogel keratoprosthesis skirt stent has special excellent biocompatibility and permeability of hydrogel and very high tensile strength; the inflammations and complications occurring after the corneal transplantation can be relieved by virtue of drugs released by the biodegradable drug-loading microspheres.

It is intended to provide a transplantation material applicable to ocular surface diseases with a need for ectocornea transplantation (i.e., an ectocornea-like sheet). Oral mucosal epithelial cells are inoculated onto an amnion and then cultured in the coexistence of supporter cells. When a layered structure of the oral mucosal epithelial cells is formed, the outermost layer is brought into contact with air, thereby inducing differentiation. Thus, an ectocornea-like sheet having an oral mucosal epithelial cell layer on the amnion is obtained.

The invention belongs to the field of tissue engineering, and particularly relates to modified acellular corneal stroma and a modification method thereof. The modification method comprises the following steps: (1) carrying out pretreatment on acellular corneal stroma; (2) reacting with the pretreated acellular corneal stroma by amino acid, and carrying out graft modification on the acellular corneal stroma; and (3) carrying out post treatment on the acellular corneal stroma subjected to graft modification, and removing the residual material in the graft modification process to obtain the modified acellular corneal stroma. The modified acellular corneal stroma has good mechanical property and biocompatibility, also has excellent rehydration water-retaining properties, can quickly restore the transparency after being implanted, and can be applied to tissue engineering research, clinical corneal transplantation and the like.

The invention provides a method of reducing ocular inflammation in an individual susceptible to ocular inflammation. The method involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Also provided is a method for reducing spread of viral infection within ocular tissues of an individual susceptible to ocular viral infection, which involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Further provided is a method of extending corneal graft survival following corneal transplantation in an individual, which involves administering to said individual an effective amount of a neutralizing agent specific for CXCL10. Additionally, the invention provides a method for identifying a compound for reducing ocular inflammation in an animal.

The invention belongs to the technical field of pharmaceutical dosage forms and nano medicine preparation, and more particularly relates to a micelle loaded with Tacrolimus or pharmaceutical salts thereof, a lyophilized preparation as well as preparation methods and applications thereof. In order to achieve the clinical application of the micelle provided by the invention, the drug loading, the encapsulation rate and the stability of the preparation need to be ensured. The micelle is prepared from biodegradable polymer materials and Tacrolimus or pharmaceutical salts thereof in parts by weight: 1 part of Tacrolimus or pharmaceutical salts thereof and 1.5-99 parts of degradable polymer materials, wherein the degradable polymer materials are diblock polymer methoxy polyethylene glycol-polycaprolactone (the molecular weight ratio of MPEG to PCL is 0.5-2), and triblock polymer polycaprolactone-polyethylene glycol-polycaprolactone (the molecular weight ratio of PCL to PEG is 0.5-3). The micelle using Tacrolimus or pharmaceutical salts thereof or the lyophilized preparation of the micelle can be used in medicines for anti-rejection in liver transplantation, kidney transplantation, lung transplantation, corneal transplantation and other organ transplantations.

The invention discloses an in-vitro construction method of bioengineering full-layer human cornea. Cell culture comprises preparation of single cell, cultivation of corneal stroma cells and preparation of corneal endothelial cells. The method comprises the following steps: washing a corneosclera ring of a donor with 100 U/ml penicillin and 80 U/ml streptomycin solution wash for three times, soaking into a 2.4 U/ml Dispase 2 solution, performing incubation in an incubator for 1 hour, lightly stripping limbal epithelium through a dissecting microscope and microscopic tweezers, soaking the stripped epithelial sheet into a 0.25 percent pancreatin-0.02 percent EDTA solution, and digesting in the incubator for 5 minutes again to obtain single cell. The in-vitro construction method of the bioengineering full-layer human cornea can be applied to an in-vitro medicine toxicity experiment, more importantly, sufficient biomechanical property is achieved, traction of a suture in penetrating keratoplasty and pressure in eyeballs after operation can be tolerated, and high biocompatibility and biological security are achieved, so the bioengineering full-layer human cornea can replace the donor's cornea to be applied to corneal transplantation.

Disclosed is a method for preparing a biocompatible tissue, the method including: providing a cornea from a tissue source through corneal incision; decellularizing the provided cornea in purified water containing charcoal for a predetermined period of time; and post-treating the decellularized corneal extracellular matrix through stirring in a hypotonic solution, so that the charcoal is used as a decellularizing agent for the cornea, thereby allowing the regeneration of a corneal tissue like in the original corneal extracellular matrix, and the preparation of a cornea without an immune rejection response and a fast regeneration effect of a patient through transplantation of the cornea can be expected.

The invention relates to the field of cell culture and particularly relates to a whole eye cornea bioengineering cultivation method. The various layers of the cornea are respectively cultivated, and the advantage is that only a cornea layer needed by a patient is cultivated when the patient does not need the transplantation of the whole cornea. According to the provided preparation method of the whole cornea, a seed cell between the cornea epidermal layer and a mesenchymal layer is an autologous cell, a corneal endothelial cell is from a donator, a large quantity of endothelial cells are obtained through cultivation, and the limit of the source of the donator is avoided. A collagen culture medium is taken as a gluing medium between the epidermal layer and the mesenchymal layer, and the intraneural growth of the human bioengineering cornea is promoted. The provided whole cornea and partial cornea both have an excellent optical property, the patients all recovers the eyesight after the operation, the cornea has a stable biochemical characteristic, the dissolution of the cornea in the later period does not exist, the biocompatibility is excellent, and no rejection reaction is caused.